Publication: Randomized phase II trial of selenomethionine as a modulator of efficacy and toxicity of chemoradiation in squamous cell carcinoma of the head and neck
| Reference | |
|---|---|
| Title | Randomized phase II trial of selenomethionine as a modulator of efficacy and toxicity of chemoradiation in squamous cell carcinoma of the head and neck |
| Topic | Selenium |
| Author | Mix, M, Singh, AK, Tills, M, Dibaj, S, Groman, A, Jaggernauth, W, Rustum, Y, Jameson, MB |
| Year | 2015 |
| Journal | World journal of clinical oncology |
| DOI | https://doi.org/10.5306/wjco.v6.i5.166 |
Author's Abstract The abstract and the information and conclusions contained therein were written by the authors of the publication.
| AIM: To investigate whether selenomethionine (SLM) reduces mucositis incidence in patients with head and neck squamous cell cancer (HNSCC) undergoing concurrent chemoradiation (CRT).
METHODS: In this multi-institutional, randomized, double-blind phase II trial, patients with Stage III or IV HNSCC received SLM 3600 μg/m² or placebo twice daily for 7 days prior to CRT, once daily during CRT, and daily for 3 weeks following CRT. CRT consisted of 70 Gy at 2 Gy per fraction with cisplatin 100 mg/m² IV on days 1, 22, and 43. RESULTS: Eighteen patients were randomized, 10 received SLM, and there were no differences in baseline factors. There was no difference in mucositis or patient-reported side effects between groups. There was no difference in overall or relapse-free survival at 12 months. CONCLUSION: Addition of SLM to CRT for HNSCC was well-tolerated but did not lower the incidence of severe mucositis or improve quality of life or survival outcomes. |
This publication is referenced in the following studies: